95
Valuation for solvency purposes Technical provisions
Ongoing validation and review processes are in place to ensure that models being used remain appropriate and
can be relied upon, including model validations, and process reviews carried out by the Internal Audit function.
Each of the US legal insurance entities
has its own independent Appointed Actuary, which is responsible for setting the assumptions, including margins for adverse deviation, and calculating the technical provisions and performing the cash flow testing.
The Actuarial Function Holder (AFH), appointed by the US board, provides at least once a year an independent opinion on adequacy and reliability of the
technical provisions, including a summary of concerns and recommendations, if any. This is documented by the AFH in an annual Actuarial Function Report.
D.2.1 Technical provisions non-life
De-recognition of the IFRS-EU value of D&A entities and change in approach for joint ventures
The de-recognition of the IFRS-EU value of Deduction and Aggregation (D&A)
entities, Other Financial Sector (OFS) entities and IFRS-SII presentational differences of joint ventures under Solvency II (instead of associate under IFRS-EU)
generates an aggregation difference of EUR (7,790) million.
Method of valuation under Solvency II
Refer to section D.2 Technical provisions for the base, models, methodology and assumptions applied for the valuation of the Solvency II technical provisions.
Material difference in valuation between Solvency II and IFRS-EU
Solvency II requires discounting of all the expected future cash flows by EIOPA described discount rates and adding a risk margin based on the cost of capital
(CoC) for non-hedgeable risks.
The Solvency II discount rate is based on the prescribed EIOPA curve
at the reporting date including the volatility adjustment where applied. The IFRS discount rate is usually a fixed rate and is set following local GAAP (Generally Accepted Accounting Principles).
Finally, presentational differences exist between IFRS-EU and Solvency II, and reclassifications are required to
comply with Solvency II requirements (e.g. annuities stemming from non-life contracts).
Reclassification
adjustments
The reclassification adjustments amounted to EUR (908) million and is mainly due to reclassification of health insurance stemming from
Aegon the Netherlands. Under IFRS the technical provisions of the health insurance are presented as Technical Provisions - non-life, while under Solvency II the technical provisions are classified under
Technical provisions - life (excluding index-linked and unit-linked).
Revaluation adjustments
The total revaluation adjustment amounted to EUR (90) million, and was mainly due to the application of different discount rates, and the application of
shorter contract boundaries under Solvency II.
D.2.2 Technical provisions life (excluding index-linked and
unit-linked contracts)
De-recognition of the IFRS-EU value of
D&A entities and change in approach for joint ventures
The de-recognition of the IFRS-EU value of Deduction and Aggregation (D&A) entities, Other Financial Sector (OFS) entities and IFRS-SII presentational differences of joint ventures under Solvency
II (instead of associate under IFRS-EU) generates an aggregation difference of EUR (87,823) million.
Method of
valuation under Solvency II
Refer to section D.2 Technical provisions above for the base, models, methodology and assumptions applied for the
valuation of the Solvency II technical provisions.
Material difference in valuation between Solvency II and IFRS-EU
Solvency II requires the inclusion of indirect overhead expenses in the expected future cash flows for calculating insurance liabilities (e.g. salaries to
general managers, auditing costs, office rent, buying new IT systems, etc.).
Another difference relates to contract boundaries. Under Solvency II, the
renewability assumption is required to be supported by legally binding obligations, rather than estimates of policyholders attrition pattern.
|
|
|
Aegon Solvency and Financial Condition Report 2020
|
|
|